Sugi Predict

Sugi Predict / Compounds / SCHEMBL992472

SCHEMBL992472

SCHEMBL992472

C[C@]1(n2ccc(N)nc2=O)C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ SLC29A1 Q99808 1/20 0.46
▸ LMNA P02545 5/20 0.46
▸ MTOR P42345 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ MDM2 Q00987 1/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ CACNA1F O60840 2/20 0.40
▸ ALB P02768 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CACNA1D Q01668 2/20 0.40
▸ CACNA1S Q13698 2/20 0.40
▸ CACNA1C Q13936 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ POLB P06746 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ DNMT1 P26358 2/20 0.35
▸ ADRB1 P08588 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118776 0.85 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL3424602 0.84 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL1939478 0.84 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL28379714 0.84 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL17027931 0.84 POLB (0.46) PDE3APDE4DSLC29A1POLBPOLA1
SCHEMBL5192208 0.84 P2RY6 (0.33) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL1962181 0.84 PDE3A (0.45) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL4971926 0.83 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL7794942 0.83 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL51650 0.83 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 — — US claimed
EP-4372091-A2 COMPOSITIONS AND METHODS FOR EDITING NUCLEIC ACIDS IN CELLS UTILIZING OLIGONUCLEOTIDES Woolf, Tod M. (US) 2024-05-22 — — EP claimed
CN-117122529-A Preparation method of injectable gel 云南贝泰妮生物科技集团股份有限公司 2023-11-28 — — CN claimed
US-20230250474-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-08-10 — — US claimed
CN-115737912-A Preparation method of hyaluronic acid microsphere composite solution preparation with slow release effect 云南云科特色植物提取实验室有限公司 2023-03-07 — — CN claimed
US-11542551-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-01-03 — — US claimed
US-20200318179-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2020-10-08 — — US claimed
CN-106232834-B Sample preparation method 牛津纳米孔技术公司 2020-09-22 — — CN claimed
US-10669578-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2020-06-02 — — US claimed
EP-3108010-B1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECH LTD (GB) 2018-11-28 — — EP claimed
US-20170067101-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2017-03-09 — — US claimed
EP-3108010-A1 SAMPLE PREPARATION METHOD Oxford Nanopore Technologies Limited (GB) 2016-12-28 — — EP claimed
WO-2015124935-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2015-08-27 — — WO claimed
US-20260117422-A1 METHODS AND COMPOSITIONS FOR GENOMIC ANALYSIS Twist Bioscience Corporation (US) 2026-04-30 — — US disclosed
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 — — US disclosed
US-20260015392-A1 MUTANT CSGG PORES OXFORD NANOPORE TECHNOLOGIES PLC (BE) 2026-01-15 — — US disclosed
WO-1994005684-A1 N4-METHYL-2'-DEOXYCYTIDINE 5'-TRIPHOSPHATE AND ITS USE IN POLYMERASE-CATALYZED NUCLEIC ACID SYNTHESES LIFE TECHNOLOGIES, INC. (US) 1994-03-17 — — WO disclosed
EP-0544824-A1 NUCLEASE RESISTANT, PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION. ISIS PHARMACEUTICALS INC (US) 1993-06-09 — — EP disclosed
WO-1992002258-A1 NUCLEASE RESISTANT, PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1992-02-20 — — WO disclosed
EP-0450370-A1 Branch migration of nucleotides ENZO BIOCHEM, INC. (US) 1991-10-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584168-B2 Sample preparation method POLN, POLRMT, POLM PDE3A 2207/4885PDE4D 962/4885SLC29A1 90/4885
US-20260117422-A1 METHODS AND COMPOSITIONS FOR GENOMIC ANALYSIS DNMT3A, BRCA1, DNMT1 PDE3A 3079/4885PDE4D 818/4885SLC29A1 2018/4885
US-20260015392-A1 MUTANT CSGG PORES NPPA, AFG3L2, SCAMP3 PDE3A 3114/4885PDE4D 3034/4885SLC29A1 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.